1. CORT announced FDA submission for relacorilant's New Drug Application. 2. This move is a significant step towards potential new revenue streams.
The FDA submission suggests progress for CORT's product pipeline, which historically leads to price increases in biotech stocks.
The FDA submission is crucial for CORT's growth, and such announcements typically have significant market implications.
The immediate market reaction may be positive due to investor sentiment towards FDA news, but sustained impact depends on clinical outcomes.